Antiseizure medication use in self‐limited epilepsies of childhood: A scoping review by the ILAE Pediatric Medical Therapies Task Force

OBJECTIVE: Self-limited focal epilepsies (SeLFEs) of childhood, including self-limited epilepsy with centrotemporal spikes (SeLECTS), self-limited epilepsy with autonomic seizures (SeLEAS), childhood occipital visual epilepsy (COVE), and photosensitive occipital lobe epilepsy (POLE), are common pediatric epilepsy syndromes with heterogeneous clinical management. We performed a scoping review to synthesize evidence regarding the use, effectiveness, safety, and discontinuation of antiseizure medications (ASMs) in children with SeLFEs. METHODS: Nine databases were searched from inception to January 2026. Eligible studies included original research reporting ASM-related outcomes in children with SeLFEs. PRISMA-ScR (Preferred Reporting Items of Systematic Reviews and Meta-Analyses, extension for scoping reviews) guidance was followed. RESULTS: Sixty-two studies met eligibility criteria, including 11 randomized controlled trials (RCTs). Most studies evaluated SeLECTS (6171 participants), whereas substantially fewer investigated SeLEAS (n = 348), COVE (n = 91), or POLE (n = 26). Evidence was highly heterogeneous and consisted predominantly of retrospective observational studies. In SeLECTS, reported 12-month seizure freedom rates after ASM treatment were approximately 72% across studies, although estimates varied considerably. Evidence for SeLEAS, COVE, and POLE was limited and derived mainly from small retrospective cohorts with heterogeneous methodologies and outcome definitions. Failure of first-line ASM therapy occurred in approximately 30% of patients. Adverse events were reported in approximately 22% of treated children and infrequently led to treatment discontinuation. RCTs generally reported similar seizure outcomes across multiple ASMs, although many trials were limited by small sample sizes and open-label designs. SIGNIFICANCE: Current evidence suggests that children with SeLFEs often achieve seizure control with ASM treatment and that adverse effects are generally manageable. However, the overall certainty of evidence remains limited because of methodological heterogeneity, predominance of retrospective studies, and limited randomized data. Important evidence gaps remain regarding the need for ASM treatment, optimal treatment duration, and timing of medication withdrawal.

Authors

Institutions

Publication Details

Journal
Epilepsia
Published
2026-11-16
DOI
https://doi.org/10.1002/epi.70559
Primary Topic
Epilepsy research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antiseizure medication use in self‐limited epilepsies of childhood: A scoping review by the ILAE Pediatric Medical Therapies Task Force

Kette D. R. Valente, Rima Nabbout, Francesco Brigo, Kelly G. Knupp et al.
4 links
Epilepsia
Epilepsy research and treatment
article

Antiseizure medication use in self‐limited epilepsies of childhood: A scoping review by the ILAE Pediatric Medical Therapies Task Force

Kette D. R. Valente, Rima Nabbout, Francesco Brigo, Kelly G. Knupp, Jithangi Wanigasinghe, Ingrid Eileen Scheffer, Simona Balestrini, Elaine C. Wirrell, Nathalie Jetté, Stéphane Auvin, Ana Carolina Coan, Julia Jacobs
article en

Abstract

OBJECTIVE: Self-limited focal epilepsies (SeLFEs) of childhood, including self-limited epilepsy with centrotemporal spikes (SeLECTS), self-limited epilepsy with autonomic seizures (SeLEAS), childhood occipital visual epilepsy (COVE), and photosensitive occipital lobe epilepsy (POLE), are common pediatric epilepsy syndromes with heterogeneous clinical management. We performed a scoping review to synthesize evidence regarding the use, effectiveness, safety, and discontinuation of antiseizure medications (ASMs) in children with SeLFEs. METHODS: Nine databases were searched from inception to January 2026. Eligible studies included original research reporting ASM-related outcomes in children with SeLFEs. PRISMA-ScR (Preferred Reporting Items of Systematic Reviews and Meta-Analyses, extension for scoping reviews) guidance was followed. RESULTS: Sixty-two studies met eligibility criteria, including 11 randomized controlled trials (RCTs). Most studies evaluated SeLECTS (6171 participants), whereas substantially fewer investigated SeLEAS (n = 348), COVE (n = 91), or POLE (n = 26). Evidence was highly heterogeneous and consisted predominantly of retrospective observational studies. In SeLECTS, reported 12-month seizure freedom rates after ASM treatment were approximately 72% across studies, although estimates varied considerably. Evidence for SeLEAS, COVE, and POLE was limited and derived mainly from small retrospective cohorts with heterogeneous methodologies and outcome definitions. Failure of first-line ASM therapy occurred in approximately 30% of patients. Adverse events were reported in approximately 22% of treated children and infrequently led to treatment discontinuation. RCTs generally reported similar seizure outcomes across multiple ASMs, although many trials were limited by small sample sizes and open-label designs. SIGNIFICANCE: Current evidence suggests that children with SeLFEs often achieve seizure control with ASM treatment and that adverse effects are generally manageable. However, the overall certainty of evidence remains limited because of methodological heterogeneity, predominance of retrospective studies, and limited randomized data. Important evidence gaps remain regarding the need for ASM treatment, optimal treatment duration, and timing of medication withdrawal.

Epilepsia
Hôpital Necker-Enfants Malades (FR), Royal Children's Hospital (AU), Mayo Clinic (US), The University of Melbourne (AU), University of Calgary (CA), Universidade de São Paulo (BR), Universidade Estadual de Campinas (UNICAMP) (BR), Institut Universitaire de France (FR), Université Paris Cité (FR), Alberta Children's Hospital (CA), Ospedale di Bolzano (IT), Assistance Publique – Hôpitaux de Paris (FR), Meyer Children's Hospital (IT), Hôpital Robert-Debré (FR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Murdoch Children's Research Institute (AU), Austin Health (AU), Institut des Maladies Génétiques Imagine (FR), UCL Queen Square Institute of Neurology (GB), Hotchkiss Brain Institute (CA), Azienda Sanitaria dell'Alto Adige (IT), University of Florence (IT), University College London (GB), University of Colorado Anschutz Medical Campus (US), University of Colombo (LK), University of Colorado Denver (US)
Good health and well-being
Epilepsy research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon